Comparing MRI and Ultrasound to Find Liver Cancer in People With Cirrhosis
Compares ultrasound and abbreviated MRI for spotting liver cancer in adults with cirrhosis.
Plain-language title generated from the registry record
Registry title: A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
Key facts
- Where
- Linköping, SwedenSee the site
Where in Sweden
- Department of gastroenterology and hepatology, University hospital in LinköpingLinköping, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mattias Ekstedt
- Trial code
- NCT07291141
- Record updated
- 19 December 2025
- Original description
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.Read full original descriptionShow less
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.
A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.
The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.
Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.
The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.
Inclusion: Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology; Age ≥18 years ≤ 84; Written informed consent from the participant.
Exclusion: Previous diagnosis of hepatic carcinoma (HCC); Previous liver transplant; Vascular liver disease; Contraindications for MRI (ferrrous material, claustrophobia); Pregnancy; Diagnosis of primary sclerosing cholangitis (PSC); Congenital liver fibrosis.